Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 May 18;65(6):e02432-20.
doi: 10.1128/AAC.02432-20. Print 2021 May 18.

Mutations in the HIV-1 3'-Polypurine Tract and Integrase Strand Transfer Inhibitor Resistance

Affiliations

Mutations in the HIV-1 3'-Polypurine Tract and Integrase Strand Transfer Inhibitor Resistance

Yuliang Wei et al. Antimicrob Agents Chemother. .
No abstract available

Keywords: HIV; integrase; polypurine tract; resistance.

PubMed Disclaimer

Figures

FIG 1
FIG 1
Replication capacity of HIV-1WT, HIV-1PPT(1), and HIV-1PPT(2). TZM-bl cells were infected with 27 ng p24 (A) or 81 ng p24 (B) of each virus. A single-copy assay for extracellular virion-associated HIV-1 RNA was used to quantify virus production, as described previously (9). Data are reported as the average of two independent experiments.

Similar articles

Cited by

References

    1. Anstett K, Brenner B, Mesplede T, Wainberg MA. 2017. HIV drug resistance against strand transfer integrase inhibitors. Retrovirology 14:36. doi:10.1186/s12977-017-0360-7. - DOI - PMC - PubMed
    1. Malet I, Subra F, Charpentier C, Collin G, Descamps D, Calvez V, Marcelin AG, Delelis O. 2017. Mutations located outside the integrase gene can confer resistance to HIV-1 integrase strand transfer inhibitors. mBio 8:e00922-17. doi:10.1128/mBio.00922-17. - DOI - PMC - PubMed
    1. Wijting I, Lungu C, Rijnders B, van der Ende ME, Pham HT, Mesplede T, Pas SD, Voermans J, Schuurman R, van de Vijver D, Boers P, Gruters RA, Boucher C, van Kampen J. 2018. HIV-1 resistance dynamics in patients with virologic failure to dolutegravir maintenance monotherapy. J Infect Dis 218:688–697. doi:10.1093/infdis/jiy176. - DOI - PubMed
    1. Giacobbi NS, Sluis-Cremer N. 2017. In vitro cross-resistance profiles of rilpivirine, dapivirine, and MIV-150, nonnucleoside reverse transcriptase inhibitor microbicides in clinical development for the prevention of HIV-1 infection. Antimicrob Agents Chemother 61:e00277-17. doi:10.1128/AAC.00277-17. - DOI - PMC - PubMed
    1. Grobler JA, Dornadula G, Rice MR, Simcoe AL, Hazuda DJ, Miller MD. 2007. HIV-1 reverse transcriptase plus-strand initiation exhibits preferential sensitivity to non-nucleoside reverse transcriptase inhibitors in vitro. J Biol Chem 282:8005–8010. doi:10.1074/jbc.M608274200. - DOI - PubMed

Publication types

MeSH terms

LinkOut - more resources